Table 1.
Baseline demographics and clinical characteristics overall and by treatment group (N = 187)
| Overall (N = 187) | Metronidazole (N = 107) | Vancomycin (N = 80) | ||
|---|---|---|---|---|
| Site | Boston (%) | 90 (48.13) | 27 (25.23) | 63 (78.75) |
| Chicago (%) | 97 (51.87) | 80 (74.77) | 17 (21.25) | |
| Age | Mean (SD) | 8.86 (4.60) | 10.15 (4.55) | 9.47 (4.67) |
| Median (Q1, Q3) | 9.63 (5.80, 13.57) | 10.22 (6.06, 13.62) | 8.40 (5.62, 13.39) | |
| [Min, Max] | [2.04, 17.88] | [2.04, 17.88] | [2.11, 17.76] | |
| Sex | Male (%) | 108 (57.75) | 65 (60.75) | 43 (53.75) |
| Female (%) | 79 (42.25) | 42 (39.25) | 37 (46.25) | |
| Race/Ethnicity | White Non-Hispanic (%) | 88 (47.06) | 55 (51.40) | 33 (41.25) |
| Black Non-Hispanic (%) | 17 (9.09) | 12 (11.21) | 5 (6.25) | |
| Hispanic (%) | 37 (19.79) | 22 (20.56) | 15 (18.75) | |
| Other (%) | 45 (24.06) | 18 (16.82) | 27 (33.75) | |
| Inflammatory bowel disease | Yes (%) | 23 (12.30) | 8 (7.48) | 15 (18.75) |
| No (%) | 164 (87.70) | 99 (92.52) | 65 (81.25) | |
| Receiving chemotherapy | Yes (%) | 58 (31.02) | 35 (32.71) | 23 (28.75) |
| No (%) | 129 (68.98) | 72 (67.29) | 57 (71.25) | |
| Hematopoietic stem cell transplant recipient | Yes (%) | 24 (12.83) | 13 (12.15) | 11 (13.75) |
| No (%) | 163 (87.17) | 94 (87.85) | 69 (86.25) | |
| Immunosuppression a (N = 24) | Yes (%) | 17 (20.83) | 10 (76.92) | 7 (63.64) |
| No (%) | 7 (29.17) | 3 (23.08) | 4 (36.36) | |
| Graft vs host disease a (N = 24) | Yes (%) | 3 (12.50) | 2 (15.38) | 1 (9.09) |
| No (%) | 21 (87.50) | 11 (84.62) | 10 (90.91) | |
| History of solid organ transplant | Yes (%) | 21 (11.23) | 8 (7.48) | 13 (16.25) |
| No (%) | 166 (88.77) | 99 (92.52) | 67 (83.75) | |
| Immunocompromised host b | Yes (%) | 88 (47.06) | 48 (44.86) | 40 (50.00) |
| No (%) | 99 (52.94) | 59 (55.14) | 40 (50.00) | |
| Past CDI diagnosis | Yes (%) | 36 (19.25) | 10 (9.35) | 26 (32.50) |
| No (%) | 151 (80.75) | 97 (90.65) | 54 (67.50) | |
| Time from last CDI diagnosis to treatment start (days) (N = 36) | Mean (SD) | 284.55 (497.90) | 773.56 (728.39) | 84.50 (87.34) |
| Median (Q1, Q3) | 82.00 (26.00, 288.00) | 340.00 (288.00, 1172.00) | 60.00 (24.00, 105.00) | |
| [Min, Max] | [14.00, 2166.00] | [63.00, 2166.00] | [14.00, 376.00] | |
| Freq. of Missing | 5 | 1 | 4 | |
| IDSA-SHEA severity | Not Severe (%) | 122 (65.24) | 65 (60.75) | 57 (71.25) |
| Severe (%) | 34 (18.18) | 19 (17.76) | 15 (18.75) | |
| Freq. of Missing | 31 | 23 | 8 | |
| Treatment start year | 2016/2017 (%) | 129 (68.98) | 97 (90.65) | 32 (40.00) |
| 2018/2019 (%) | 58 (31.02) | 10 (9.35) | 48 (60.00) |
CDI, C. difficile infection; IDSA, Infectious Diseases Society of America; SHEA, Society for Healthcare Epidemiology of America.
a
Immunosuppression (defined as receiving immunosuppressive agents) and graft vs host disease were assessed at the time of CDI diagnosis and only among hematopoietic stem cell transplant recipients.
b
Immunocompromised host was defined as receiving chemotherapy and/or prior hematopoietic stem cell or solid organ transplant.